| Ticker |
GNCAQ
|
| CIK | 0001457612 |
| SIC | 2836 |
| Sector | Manufacturing |
| Industry Category | Pharmaceutical Products |
| Industry Group | Biological Products, Except Diagnostic Substances |
| Address | 100 ACORN PARK DRIVE, CAMBRIDGE, MA, 02140 |
| Website | genocea.com |
| Phone | 6178768191 |
| CEO | William D. Clark |
| Employees | 70 |
Our team will help you customize a package that meets the needs of your business.
Request a Consultation|
Standardized FinancialsdocsIntrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals. For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards. Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics: |
|||||||||||||||||||||
|
Income Statement
|
Balance Sheet
|
||||||||||||||||||||
|
Cash Flow Statement
|
Calculations
|
||||||||||||||||||||
|
Latest NewsdocsIntrinio provides up-to-date news articles on every US company from various sources. Here are several examples: |
Herpes Simplex Virus (HSV) Vaccines Market 2024, Business Growing Strategies, Regional Growth by 2031: Sanofi S.A.Herpes Simplex Virus Vaccines Market. BURLINGAME, CALIFORNIA, UNITED STATES, February 13, 2024/ EINPresswire.com/-- Global Herpes Simplex Virus Vaccines Market 2024 research report represents a detailed overview of the current market situation and forecast till 2031. The report includes multiple research studies, such as market dynamics, pricing analysis,... Herpes Simplex Virus (HSV) Vaccines Market 2024, Business Growing Strategies, Regional Growth by 2031: Sanofi S.A.Herpes Simplex Virus Vaccines Market. BURLINGAME, CALIFORNIA, UNITED STATES, February 13, 2024/ EINPresswire.com/-- Global Herpes Simplex Virus Vaccines Market 2024 research report represents a detailed overview of the current market situation and forecast till 2031. The report includes multiple research studies, such as market dynamics, pricing analysis,... Genocea Biosciences to shut downGenocea Biosciences Inc. on Tuesday told investors it plans to shut down and lay off all remaining employees. The company said it gave notice to The Nasdaq Stock Market Inc. for its plans to voluntarily delist its common stock and said it plans to file a Form 25 with the Securities and Exchange Commission by June 2. Genocea was developing immunotherapies for people with cancer. The company's stock had tumbled 94.7% this year, while the broader S&P 500 is down 17.3%. Three weeks after layoffs, Genocea shuts down entirelyThe Cambridge company made the decision just three weeks after announcing it was laying off 65% of its staff and exploring a sale. Genocea Closes Shop, Delists From NASDAQGenocea Biosciences Inc's (NASDAQ: GNCA) board has voted to wind down the company's ongoing operations and terminate the remaining employees except those deemed necessary to complete an orderly wind down. Yesterday, the company delivered formal notice to The Nasdaq Stock Market Inc of its intent to delist voluntarily and its plans to file a Form 25 with the SEC by June 2 to effect the voluntary delisting. The company received a letter that it was not in compliance with the requirement of the Nas |
